EBMT 2021 | Teclistamab in relapsed/refractory multiple myeloma
Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute and Atrium Health in Charlotte, NC, shares an update on a Phase I trial (NCT04557098) of teclistamab, a B-cell maturation antigen (BCMA) and CD3-targeting bispecific antibody, for the treatment of relapsed/refractory multiple myeloma. Teclistamab is currently being trialled in a dose-escalation study (NCT03145181) with both subcutaneous and intravenous delivery. Cytokine release syndrome (CRS) has been observed in 55% of patients overall, and in 64% of patients receiving the recommended Phase II dose delivered subcutaneously. All CRS was grade one or two. The overall response rate for the subcutaneous population was 73%. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx and Takeda; and has received speaking fees from Celgene, Janssen, Sanofi and Takeda.
